The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: Results from a randomized, exploratory study

International Clinical Psychopharmacology

Volumn 31, Issue 4, 2016, Pages 192-201

  Citrome, Leslie ^a,e   Ota, Ai ^c   Nagamizu, Kazuhiro ^c   Perry, Pamela ^b   Weiller, Emmanuelle ^d   Baker, Ross A ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^c OTSUKA PHARMACEUTICAL CO LTD   (Japan)

^d H LUNDBECK A S   (Denmark)

^e NONE   (United States)

Author keywords

akathisia; antipsychotic; aripiprazole; Barratt Impulsiveness Scale 11 item; brexpiprazole; Positive and Negative Syndrome Scale; schizophrenia; Specific Levels of Functioning Scale

Indexed keywords

ARIPIPRAZOLE; BREXPIPRAZOLE; PROLACTIN; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; SEROTONIN RECEPTOR AFFECTING AGENT; THIOPHENE DERIVATIVE;

ABNORMAL INVOLUNTARY MOVEMENT SCALE; ACUTE DISEASE; ACUTE SCHIZOPHRENIA; ADULT; AGED; AKATHISIA; ARTICLE; BACKACHE; BARNES AKATHISIA SCALE; BARRATT IMPULSIVENESS SCALE; BODY MASS; BODY WEIGHT; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COLUMBIA SUICIDE SEVERITY RATING SCALE; CONSTIPATION; CONTROLLED STUDY; DETECTION TASK; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DSM-IV-TR; DYSPEPSIA; ELECTROCARDIOGRAM; EXPERIMENTAL COGNITIVE TEST; EXPLORATORY RESEARCH; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GROTON MAZE LEARNING TASK; HEADACHE; HUMAN; IDENTIFICATION TASK; IMPULSIVENESS; INTERACTIVE VOICE RESPONSE SYSTEM; INTERNATIONAL SHOPPING LIST TASK; MAJOR CLINICAL STUDY; MALE; METABOLIC PARAMETERS; MINI INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; MULTICENTER STUDY; MUSCLE SPASM; NAUSEA; ONE BACK MEMORY TASK; ONE CARD LEARNING TASK; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT SAFETY; PHASE 3 CLINICAL TRIAL; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCHIZOPHRENIA; SEDATION; SENSITIVITY ANALYSIS; SIDE EFFECT; SIMPSON-ANGUS SCALE; SOCIAL EMOTIONAL COGNITION TEST; TOOTH PAIN; TWO BACK MEMORY TASK; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA; CLINICAL TRIAL; DOSE RESPONSE; DRUG EFFECTS; MIDDLE AGED; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; ARIPIPRAZOLE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; QUINOLONES; SCHIZOPHRENIA; SEROTONIN AGENTS; THIOPHENES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 84960344877     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000123     Document Type: Article

References (47)

1. Barnes TR (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
2. Blier P, Ward NM (2003). Is there a role for 5-HT1A agonists in the treatment of depression? Biol Psychiatry 53:193-203.
3. Carliner H, Collins PY, Cabassa LJ, McNallen A, Joestl SS, Lewis-Fernández R (2014). Prevalence of cardiovascular risk factors among racial and ethnic minorities with schizophrenia spectrum and bipolar disorders: a critical literature review. Compr Psychiatry 55:233-247.
4. Celada P, Puig M, Amargós-Bosch M, Adell A, Artigas F (2004). The therapeutic role of 5-HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci 29:252-265.
5. Citrome L (2007). The psychopharmacology of violence with emphasis on schizophrenia, part 1: acute treatment. J Clin Psychiatry 68:163-164.
6. Citrome L (2009). Quantifying risk: the role of absolute and relative measures in interpreting risk of adverse reactions from product labels of antipsychotic medications. Curr Drug Saf 4:229-237.
7. Citrome L (2013). A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs 27:879-911.
8. Citrome L (2015a). Brexpiprazole: a new dopamine D2 receptor partial agonist for the treatment of schizophrenia and major depressive disorder. Drugs Today 51:397-414.
9. Citrome L (2015b). Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic-what is the number needed to treat, number needed to harm and likelihood to be helped or harmed? Int J Clin Pract 69:978-997.
10. Citrome L, Ketter TA (2013). When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed. Int J Clin Pract 67:407-411.
11. Citrome L, Volavka J (2014). Review: 15 antipsychotic drugs are more effective than placebo for the treatment of schizophrenia, but vary in their tolerability. Evid Based Ment Health 17:9.
12. Correll CU (2010). From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry 25 (Suppl 2):S12-S21.
13. Correll CU, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. (2015). Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry 172:870-880.
14. Croxtall JD (2012). Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs 26:155-183.
15. De Berardis D, Marini S, Serroni N, Iasevoli F, Tomasetti C, de Bartolomeis A, et al. (2015). Targeting the noradrenergic system in posttraumatic stress disorder: a systematic review and meta-analysis of prazosin trials. Curr Drug Targets 16:1094-1106.
16. De Hert M, Yu W, Detraux J, Sweers K, van Winkel R, Correll CU (2012a). Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis. CNS Drugs 26:733-759.
17. De Hert M, Detraux J, van Winkel R, Yu W, Correll CU (2012b). Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114-126.
18. Dixon L, Perkins D, Calmes C (2010). Guideline Watch (September 2009): practice guideline for the treatment of patients with schizophrenia. Arlington, VA: American Psychiatric Publishing, Inc. Available at: http://psychiatryonline. org/pb/assets/raw/sitewide/practice-guidelines/guidelines/schizophrenia-wa tch.pdf [Accessed 19 February 2016].
19. Fleischhacker WW (2005). Aripiprazole. Expert Opin Pharmacother 6:2091-2101.
20. Guy W (1976). ECDEU assessment manual for psychopharmacology. Rockville, MD: US Department of Health, Education and Welfare.
21. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, Ali MW (2002). Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63:763-771.
22. Kane JM, Barnes TR, Correll CU, Sachs G, Buckley P, Eudicone J, et al. (2010). Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short-and long-term aripiprazole trials. J Psychopharmacol 24:1019-1029.
23. Kane JM, Peters-Strickland T, Baker RA, Hertel P, Eramo A, Jin N, et al. (2014). Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry 75:1254-1260.
24. Kane JM, Skuban A, Ouyang J, Hobart M, Pfister S, McQuade RD, et al. (2015). A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res 164:127-135.
25. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
26. 2A receptor antagonists for the treatment of neuroleptic-induced akathisia: a systematic review and meta-analysis. Int J Neuropsychopharmacol 17:823-832.
27. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (2013). Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951-962.
28. Levi L, Ballon JS, Kantrowitz JT (2013). Investigational treatments for cognitive impairment in schizophrenia. Curr Psychiatry 12:38-43.
29. Maeda K, Lerdrup L, Sugino H, Akazawa H, Amada N, McQuade RD, et al. (2014a). Brexpiprazole II: antipsychotic-like and procognitive effects of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:605-614.
30. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, et al. (2014b). Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther 350:589-604.
31. Nuechterlein KH, Green MF, Kern RS, Baade LE, Barch DM, Cohen JD, et al. (2008). The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. Am J Psychiatry 165:203-213.
32. Otsuka Pharmaceutical Co. Ltd (2015). REXULTI® (brexpiprazole) US prescribing information. Otsuka Pharmaceutical Co. Ltd. Available at: http://otsuka-us.com/products/Documents/Rexulti.PI.pdf [Accessed 18 February 2016].
33. Otsuka Pharmaceutical Co. Ltd (2016). ABILIFY® (aripiprazole) US prescribing information. Otsuka Pharmaceutical Co. Ltd. Available at: http://otsuka-us. com/products/Documents/Abilify.PI.pdf [Accessed 18 February 2016].
34. Ouzir M (2013). Impulsivity in schizophrenia: a comprehensive update. Aggress Violent Behav 18:247-254.
35. Patton JH, Stanford MS, Barratt ES (1995). Factor structure of the Barratt impulsiveness scale. J Clin Psychol 51:768-774.
36. Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, et al. (2011). The Columbia-Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. Am J Psychiatry 168:1266-1277.
37. Reddy LF, Lee J, Davis MC, Altshuler L, Glahn DC, Miklowitz DJ, Green MF (2014). Impulsivity and risk taking in bipolar disorder and schizophrenia. Neuropsychopharmacology 39:456-463.
38. Saha S, Chant D, Welham J, McGrath J (2005). A systematic review of the prevalence of schizophrenia. PLoS Med 2:e141.
39. Schneider LC, Struening EL (1983). SLOF: a behavioral rating scale for assessing the mentally ill. Soc Work Res Abstr 19:9-21.
40. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, et al. (2003). Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411.
41. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. (1998). The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (Suppl 20):22-33.
42. Simpson GM, Angus JW (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11-19.
43. Stahl SM (2008). Stahl's essential psychopharmacology. Available at: http://stahlonline.cambridge.org/essential-4th-chapter.jsf?page = chapter5-sum mary.htm&name =Chapter%205&title=Summary [Accessed 22 September 2015].
44. Stahl SM (2013). Role of α1 adrenergic antagonism in the mechanism of action of iloperidone: reducing extrapyramidal symptoms. CNS Spectr 18: 285-288.
45. Volavka J, Citrome L (2009). Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother 10:1917-1928.
46. Wang LY, Shofer JB, Rohde K, Hart KL, Hoff DJ, McFall YH, et al. (2009). Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatry 17:744-751.
47. Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, et al. (2005). The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66:1122-1129.